Clinical Ink merges with CentrosHealth to create new trial tech platform

By Zachary Brennan

- Last updated on GMT

Clinical Ink merges with CentrosHealth to create new trial tech platform
eSource solution provider Clinical Ink is merging with CentrosHealth, a provider of mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO). 

The combination of the companies aims to create a clinical trial technology platform differentiated by its ability to conduct paperless clinical trials.

Clinical Ink also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for Clinical Ink to expand operational capabilities and further develop this paperless clinical trial platform.

Through the use of CentrosHealth and Clinical Ink’s tools, research sponsors can receive all of their data, both from the site and the patient, in real-time, which can reduce the cost, time, and complexity of the trial process. The Clinical Ink approach to eSource and mobile data capture has been endorsed by both FDA and EMA, the company claims, as it’s a component of risk-based monitoring approaches to clinical research oversight.

Jeremy Sohn, Founder/CEO of CentrosHealth, said: “Our platform seamlessly integrates clinical trial activities such as medication reminders, visit scheduling, activity measurements and ePRO into patients’ every-day life through personalized notifications, text messages, calendar integration, and a highly functional mobile application on their personal cellphone​.”

Novartis Deal

In addition to the merger, Clinical Ink entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials.

Ed Seguine, CEO of Clinical Ink, said: “The involvement of Novartis is a significant validation of our pioneering efforts to create a completely paperless clinical trial platform and to reduce the cost, time and complexity of clinical research​.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars